Endometriosis—the role of medroxyprogesterone acetate

Anthony A. Luciano
In: Journal of Obstetrics and Gynaecology · 1992 · vol. 12(sup2) , pp. S38–S44 · doi:10.3109/01443619209045611 · W2060958448
article OA: closed CC0
View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This review discusses the prevalence and impact of endometriosis and explores the role of medroxyprogesterone acetate as a treatment option for this progressive disease.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

SummaryEndometriosis is a progressive, often debilitating disease which affects 10 to 15 per cent of women during their reproductive years (Williams and Pratt, 1977; Schmidt 1985). Among gynaecological disorders, endometriosis is second only to leiomyomata in frequency and accounts for 25 per cent of all laparotomies performed by gynaecologists. (Hassan, 1976). Although not usually life threatening, endometriosis may significantly impair health and fertility potential. Selection of optimal treatment is therefore of the utmost clinical significance, as new and improved methods of treatment are continually being sought with the hope of finding a cure for this pervasive disease.

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (37)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK